Fig. 1: Schematic summarizing key data regarding cardiovascular adverse events associated with cellular immunotherapies.
From: Cardiovascular complications of cellular immunotherapies and associated risk factors
Adverse event types are reported as the range of incidence (in %) across studies. ACS acute coronary syndrome, B-ALL B-cell acute lymphocytic leukemia, BiTE bispecific T-cell engager, CAR chimeric antigen receptor, CLL chronic lymphocytic leukemia, CTRCD cancer therapy-related cardiac dysfunction, DLBCL diffuse large B-cell lymphoma, HF heart failure, IL interleukin, LVSD left ventricular systolic dysfunction, MI myocardial infarction, MM multiple myeloma, NHL non-Hodgkins lymphoma, NSCLC non-small cell lung cancer, TIL tumor-infiltrating lymphocyte.
